Solid Biosciences Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M |
| Operating expenses | $179.2M | $129.7M | $104.3M | $114.5M | $85.9M |
| Cash from operations | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M |
| Capital expenditure | $1.2M | $654,000 | $1.5M | $3.0M | $1.3M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M |
| Impairments | — | $0 | $400,000 | $0 | $92,000 |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
Shares outstanding 98.4M · Free float 76.7%
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.